NNOX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Nano-X Imaging Ltd (NNOX) is not a strong buy for a beginner, long-term investor at this time. The stock has significant financial challenges, bearish technical indicators, and lacks positive trading signals. While there are some positive catalysts, such as distribution agreements and FDA approval, these are overshadowed by the company's poor financial performance, legal investigations, and declining stock price. A hold recommendation is more appropriate until clearer signs of financial stability and growth emerge.
The technical indicators for NNOX are bearish. The MACD is negative and expanding downward, RSI is neutral but leaning oversold at 21.678, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with S1 at 1.844 and S2 at 1.523, indicating further downside risk.
Recent distribution agreement with Elite Surgical.
FDA approval for image enhancement capabilities.
Revenue growth of 24% YoY in Q4 2025.
Significant net loss of $33.4 million in Q4 2025, up 137% YoY.
EPS of -$0.50, missing expectations by $0.
Legal investigation by Bragar Eagel & Squire, P.C. for potential securities law violations.
CFO resignation announcement, raising concerns about leadership stability.
Stock price plummeted 25% post-earnings report.
In Q4 2025, revenue increased by 24% YoY to $3.72 million, but missed expectations by $0.27 million. Net income worsened significantly, with a loss of $33.4 million, up 137% YoY, primarily due to a $17.5 million impairment charge. EPS was -$0.50, up 117% YoY, but still below expectations. Gross margin remains negative at -97.26%.
Alliance Global lowered the price target from $7 to $5 but maintained a Buy rating. The firm acknowledges the company's potential for significant revenue growth by 2026 but remains cautious due to execution risks and recent financial underperformance.
